NCT00897715View on ClinicalTrials.gov

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2013

Primary Completion Date

February 25, 2015

Study Completion Date

May 8, 2015

Conditions
Chronic Kidney DiseaseCardiovascular Disease
Interventions
DRUG

Rilonacept

160 mg of rilonacept administered subcutaneously once a week for 12 weeks

DRUG

Placebo

160 mg of placebo administered subcutaneously once a week for 12 weeks

Trial Locations (2)

37232

Vanderbilt University, Nashville

37212-2637

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT00897715 - Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra) | Biotech Hunter | Biotech Hunter